ACS chemical neuroscience molecule spotlight on savella.
Savella (milnacipran), a selective serotonin and noradrenaline reuptake inhibitor, was approved by the FDA on January 14th, 2009, for the treatment of fibromyalgia.
Vanderbilt University, Vanderbilt University Medical Center Department of Pharmacology, and Vanderbilt Program in Drug Discovery, Nashville, Tennessee, USA.
Corey R
CR
Hopkins
D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D003521:Cyclopropanes / Q000494:pharmacology* / Q000627:therapeutic use; D017277:Drug Approval; D005356:Fibromyalgia / Q000188:drug therapy*; D006801:Humans; D000078764:Milnacipran; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D018759:Adrenergic Uptake Inhibitors; D003521:Cyclopropanes; D000078764:Milnacipran; D017367:Selective Serotonin Reuptake Inhibitors